CG Oncology Exceeds Even The 'Most Bullish Conversations;' Shares Break Out
CG Oncology (CGON) said Monday its experimental bladder cancer treatment cut the risk of recurrence by 68%. The news sent the biotech stock flying into breakout territory. "We see these results as meaningfully exceeding both the powering expectations (~30%) and investor expectations (~40%), and even in our most bullish conversations we did not hear investors expect a risk reduction greater…